KR102591136B1 - 집단 기반 면역원성 펩타이드 확인 플랫폼 - Google Patents

집단 기반 면역원성 펩타이드 확인 플랫폼 Download PDF

Info

Publication number
KR102591136B1
KR102591136B1 KR1020197029094A KR20197029094A KR102591136B1 KR 102591136 B1 KR102591136 B1 KR 102591136B1 KR 1020197029094 A KR1020197029094 A KR 1020197029094A KR 20197029094 A KR20197029094 A KR 20197029094A KR 102591136 B1 KR102591136 B1 KR 102591136B1
Authority
KR
South Korea
Prior art keywords
polypeptide
hla class
population
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197029094A
Other languages
English (en)
Korean (ko)
Other versions
KR20190134636A (ko
Inventor
줄리아나 리스지에위츠
레벤테 몰나르
에니코 알. 토케
조세프 토스
오소랴 로링츠
졸트 치즈조부스키
에스터 소모기
카탈린 판탸
모니카 메게시
Original Assignee
트레오스 바이오 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61386864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102591136(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP17159243.9A external-priority patent/EP3370065A1/en
Priority claimed from EP17159242.1A external-priority patent/EP3369431A1/en
Priority claimed from GBGB1703809.2A external-priority patent/GB201703809D0/en
Application filed by 트레오스 바이오 리미티드 filed Critical 트레오스 바이오 리미티드
Publication of KR20190134636A publication Critical patent/KR20190134636A/ko
Application granted granted Critical
Publication of KR102591136B1 publication Critical patent/KR102591136B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
KR1020197029094A 2017-03-03 2018-03-02 집단 기반 면역원성 펩타이드 확인 플랫폼 Active KR102591136B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17159243.9A EP3370065A1 (en) 2017-03-03 2017-03-03 Immunogenic peptides
EP17159243.9 2017-03-03
EP17159242.1 2017-03-03
EP17159242.1A EP3369431A1 (en) 2017-03-03 2017-03-03 Vaccine
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
GB1703809.2 2017-03-09
PCT/EP2018/055232 WO2018158457A1 (en) 2017-03-03 2018-03-02 Population-based immunogenic peptide identification platform

Publications (2)

Publication Number Publication Date
KR20190134636A KR20190134636A (ko) 2019-12-04
KR102591136B1 true KR102591136B1 (ko) 2023-10-17

Family

ID=61386864

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197029094A Active KR102591136B1 (ko) 2017-03-03 2018-03-02 집단 기반 면역원성 펩타이드 확인 플랫폼
KR1020197029093A Active KR102723248B1 (ko) 2017-03-03 2018-03-02 펩타이드 백신
KR1020247034375A Pending KR20240156643A (ko) 2017-03-03 2018-03-02 펩타이드 백신
KR1020197029092A Active KR102549625B1 (ko) 2017-03-03 2018-03-02 개인화된 면역원성 펩타이드 확인 플랫폼

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197029093A Active KR102723248B1 (ko) 2017-03-03 2018-03-02 펩타이드 백신
KR1020247034375A Pending KR20240156643A (ko) 2017-03-03 2018-03-02 펩타이드 백신
KR1020197029092A Active KR102549625B1 (ko) 2017-03-03 2018-03-02 개인화된 면역원성 펩타이드 확인 플랫폼

Country Status (16)

Country Link
US (9) US10213497B2 (https=)
EP (3) EP3589951A1 (https=)
JP (4) JP7751374B2 (https=)
KR (4) KR102591136B1 (https=)
CN (4) CN110651189B (https=)
AU (3) AU2018228785B2 (https=)
BR (3) BR112019018307A2 (https=)
CA (3) CA3054871A1 (https=)
CL (4) CL2019002533A1 (https=)
CO (3) CO2019010503A2 (https=)
IL (3) IL268920B2 (https=)
MA (3) MA47683A (https=)
MX (3) MX2019010461A (https=)
SG (3) SG11201906765UA (https=)
WO (3) WO2018158455A1 (https=)
ZA (2) ZA201904725B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072990A1 (en) * 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
CN110651189B (zh) * 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
GB201814361D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
TW202028224A (zh) * 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TW202039535A (zh) * 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
EP4100051A2 (en) * 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
KR102159921B1 (ko) * 2020-03-24 2020-09-25 주식회사 테라젠바이오 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
EP4126027A1 (en) 2020-04-03 2023-02-08 PepTC Vaccines Limited Coronavirus vaccine
US20230024150A1 (en) * 2020-04-20 2023-01-26 NEC Laboratories Europe GmbH Method and system for optimal vaccine design
CN112048001B (zh) * 2020-09-08 2022-04-05 南方科技大学 一种肿瘤新生抗原多肽及其应用
CN116601713A (zh) * 2020-09-12 2023-08-15 阿斯利康(英国)有限公司 用于抗her2抗体-药物缀合物疗法的评分方法
KR102278727B1 (ko) * 2020-09-16 2021-07-19 주식회사 테라젠바이오 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
WO2023017768A1 (ja) 2021-08-10 2023-02-16 日本電気株式会社 情報処理システム及び情報処理方法
TWI898159B (zh) 2021-10-04 2025-09-21 日商日本電氣股份有限公司 管理方法、管理系統及電子健康紀錄系統
US20240424094A1 (en) * 2021-10-06 2024-12-26 CancerVAX Inc. Methods and compositions for cancer treatment
US20250297036A1 (en) * 2022-04-27 2025-09-25 POSTECH Research and Business Development Foundation Method for constructing hotspot-derived peptide-nucleic acid hybrid molecules on basis of in vitro selection
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
CN119731659A (zh) 2022-08-17 2025-03-28 日本电气株式会社 信息处理系统、信息处理方法及程序
GB202216453D0 (en) 2022-11-04 2022-12-21 Lisziewicz Julianna Identification of antigens which induce t-cell responses
JP7835418B1 (ja) * 2025-01-14 2026-03-25 国立大学法人神戸大学 がんワクチンの効果予測

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824678A (zh) 2005-02-25 2006-08-30 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
US20100074925A1 (en) 2006-09-21 2010-03-25 Vaxil Biotherapeutics Ltd Antigen specific multi epitope vaccines
US20170032082A1 (en) 2015-10-12 2017-02-02 Nantomics, Llc Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
CN1225590A (zh) 1996-03-11 1999-08-11 埃皮曼尼公司 对hla分子结合亲和力提高的肽
US6617434B1 (en) * 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
CN1910284B (zh) 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
CA2566506A1 (en) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
EP1842911A4 (en) 2005-01-25 2008-12-10 Nec Corp HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
ES2523172T3 (es) 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2042600A1 (en) * 2007-09-28 2009-04-01 Commissariat A L'energie Atomique A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications
KR101648146B1 (ko) 2008-03-31 2016-08-16 텔라 가부시키가이샤 Ｍｈｃ 클래스 ⅱ 분자에 제시되는 서바이빈의 부분 펩타이드 및 그의 용도
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0818065D0 (en) * 2008-10-02 2008-11-05 Cancer Rec Tech Ltd Immunogenic peptides and uses thereof
US20120244145A1 (en) * 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
RS61173B1 (sr) * 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015143335A1 (en) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
WO2016040900A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) * 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
BR112017022845A2 (pt) * 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
GB201604755D0 (en) 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
JP2020503840A (ja) 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN110651189B (zh) * 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
EP3731876A4 (en) 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
JP2021526365A (ja) 2018-05-18 2021-10-07 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 改善された標的化ｔ細胞療法
US20210213066A1 (en) 2018-05-18 2021-07-15 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
CA3126064A1 (en) 2019-01-07 2020-07-16 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
WO2020146434A2 (en) 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824678A (zh) 2005-02-25 2006-08-30 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
US20100074925A1 (en) 2006-09-21 2010-03-25 Vaxil Biotherapeutics Ltd Antigen specific multi epitope vaccines
US20170032082A1 (en) 2015-10-12 2017-02-02 Nantomics, Llc Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Akira et al, Experimental and Therapeutic Medicine (2011), vol 2, pp 109-117.
Mohini Rajasagi et al, Blood (2014.), vol 124, no 3, pp 453-462.
Santoro Rosa et al, AIDS Research and Human Retroviruses (2015.11.1.), vol 31, no 11, pp 1077-1088.
Satarudra Prakash Singh et al, Human Immunology (2016.), vol 77, no 3, pp 295-306.
Singh Satarudra Prakash et al, Human Immunology (2015.11.14.), vol 77, no 3, pp 295-306.

Also Published As

Publication number Publication date
US20190240302A1 (en) 2019-08-08
ZA201904725B (en) 2024-01-31
CL2019002532A1 (es) 2020-02-07
SG11201906765UA (en) 2019-08-27
JP7437939B2 (ja) 2024-02-26
US20220072114A1 (en) 2022-03-10
MA47678A (fr) 2021-05-26
KR102549625B1 (ko) 2023-06-28
US20230405100A1 (en) 2023-12-21
AU2018228786A1 (en) 2019-08-01
CN110651188B (zh) 2024-02-02
KR102723248B1 (ko) 2024-10-29
CN110621334A (zh) 2019-12-27
CA3054866A1 (en) 2018-09-07
US20220111025A1 (en) 2022-04-14
US20180264094A1 (en) 2018-09-20
US20220031823A1 (en) 2022-02-03
WO2018158456A1 (en) 2018-09-07
SG11201907524UA (en) 2019-09-27
US20220111024A1 (en) 2022-04-14
MX2019010460A (es) 2020-01-09
CO2019010503A2 (es) 2020-01-17
JP7751374B2 (ja) 2025-10-08
CL2019002534A1 (es) 2020-02-07
JP2020511672A (ja) 2020-04-16
IL268917A (en) 2019-10-31
JP2023051941A (ja) 2023-04-11
IL268919B2 (en) 2023-10-01
WO2018158455A1 (en) 2018-09-07
EP3589954A1 (en) 2020-01-08
CL2022002836A1 (es) 2023-06-16
ZA201904723B (en) 2024-01-31
CL2019002533A1 (es) 2020-02-07
MA47683A (fr) 2020-01-08
AU2018226566A1 (en) 2019-08-01
MA47677A (fr) 2020-01-08
US11213578B2 (en) 2022-01-04
US20180264095A1 (en) 2018-09-20
CN110651188A (zh) 2020-01-03
AU2018228785A1 (en) 2019-08-01
CN110651189B (zh) 2024-10-25
US11628211B2 (en) 2023-04-18
JP7831948B2 (ja) 2026-03-17
BR112019018312A2 (pt) 2020-03-31
IL268920B2 (en) 2025-05-01
JP2020514413A (ja) 2020-05-21
CO2019010524A2 (es) 2020-01-17
KR20190134636A (ko) 2019-12-04
CO2019010698A2 (es) 2020-01-17
IL268917B (en) 2022-12-01
CA3054861A1 (en) 2018-09-07
BR112019018307A2 (pt) 2020-03-31
EP3589951A1 (en) 2020-01-08
IL268920B1 (en) 2025-01-01
US11426452B2 (en) 2022-08-30
SG11201907402SA (en) 2019-09-27
MX2019010459A (es) 2020-01-09
CA3054871A1 (en) 2018-09-07
KR20190133177A (ko) 2019-12-02
WO2018158457A1 (en) 2018-09-07
JP2020510698A (ja) 2020-04-09
US10213497B2 (en) 2019-02-26
KR20240156643A (ko) 2024-10-30
AU2018228786B2 (en) 2025-03-06
US20180250399A1 (en) 2018-09-06
KR20190133010A (ko) 2019-11-29
MX2019010461A (es) 2020-01-09
IL268920A (en) 2019-10-31
BR112019018313A2 (pt) 2020-05-19
IL268917B2 (en) 2023-04-01
IL268919A (en) 2019-10-31
CN110651189A (zh) 2020-01-03
AU2018226566B2 (en) 2025-01-23
EP3589310A1 (en) 2020-01-08
IL268919B1 (en) 2023-06-01
CN119371510A (zh) 2025-01-28
AU2018228785B2 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
KR102591136B1 (ko) 집단 기반 면역원성 펩타이드 확인 플랫폼
US20220160854A1 (en) Composition and process for preparing vaccine
KR102746607B1 (ko) 면역유전적 암 스크리닝 검사
EA045702B1 (ru) Платформа для идентификации иммуногенных пептидов популяционного уровня
EA045699B1 (ru) Персонализированная платформа для идентификации иммуногенного пептида
EA048805B1 (ru) Процесс получения вакцинной композиции
EA048432B1 (ru) Вакцина

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000